Oral Minoxidil Gains Traction as Potential Breakthrough in Hair Loss Treatment

A growing body of research suggests oral minoxidil, initially developed as a blood pressure medication, is emerging as a promising and accessible treatment option for various types of hair loss.

For years, individuals experiencing hair thinning have sought effective solutions, often with limited success. Recent studies, including a 2021 review in the Journal of the American Academy of Dermatology, indicate that low-dose oral minoxidil (LDOM) produces clinically meaningful improvements in hair density for those with androgenetic alopecia and other forms of alopecia. This offers a potential alternative when topical treatments are ineffective or poorly tolerated. A 2024 randomized trial published in JAMA Dermatology found similar efficacy between oral minoxidil and topical minoxidil, suggesting it’s a practical alternative.

Biotech firms are currently testing extended-release formulations of oral minoxidil, aiming to provide a steady release of the medication over 12–24 hours, potentially maximizing results while minimizing side effects. Veradermics, among others, is developing such formulations, with early phase-2 trials showing promising results. While not yet FDA-approved for hair loss in most oral forms, the potential for a standardized, accessible prescription option is increasing. This development could significantly impact the $4 billion hair loss treatment market.

However, medical professionals emphasize the importance of careful screening and monitoring. Potential side effects, such as hypertrichosis (excess hair growth), light-headedness, and fluid retention, require medical oversight, particularly for individuals with pre-existing cardiovascular conditions. Dermatologists recommend a thorough evaluation, including blood pressure checks and, for women of childbearing age, a pregnancy test, before initiating treatment. Further long-term safety data is still needed, as highlighted in a 2025 systematic review published in Frontiers in Pharmacology.

Researchers are continuing trials, including those focused on extended-release formulations, to determine optimal dosing and long-term risks, with results expected to inform future FDA approval pathways.